Smart nanoparticles as targeting platforms for HIV infections

Area of Science:

• Nanomedicine
• Virology
• Drug Delivery

Background:

• Highly Active Anti-retroviral Therapy (HAART) has reduced Human Immunodeficiency Virus (HIV) incidence but faces challenges like drug resistance and viral reservoirs.
• Existing antiretroviral therapies are limited by drug resistance, viral reservoirs, and anatomical barriers.

Purpose of the Study:

• To explore the potential of smart nanoparticles with stimuli-responsive release for improved antiretroviral drug delivery.
• To draw parallels between nanocarrier design for HIV therapy and cancer chemotherapy.
• To discuss the role of nanomaterials in preventing HIV transmission.

Main Methods:

• Reviewing strategic similarities in nanocarrier design for HIV and cancer therapy.
• Identifying stimuli-responsive triggers for antiretroviral drug release (e.g., semen, enzymes, temperature, magnetic field, light, ultrasound).
• Discussing the application of nanomicrobicides and virus-mimetic nanoparticles for HIV prevention.

Main Results:

• Smart nanoparticles can be designed for passive and active targeting, similar to cancer chemotherapy nanocarriers.
• Stimuli-responsive release mechanisms offer potential for enhanced antiretroviral drug delivery.
• Nanomaterials show promise for both treatment and prevention of HIV infection.

Conclusions:

• Smart nanoparticles represent a promising strategy to overcome current limitations in Human Immunodeficiency Virus (HIV) treatment.
• Further research into stimuli-responsive nanocarriers, including light and ultrasound triggers, is warranted for HIV therapy.
• Nanomaterials offer potential solutions for HIV prevention and achieving global health goals.